Michael Hedenus

2.2k citations

42 papers · 1.6k indexed · h-index 18

Impact in

Hematology top 0.5%
- Erythropoietin and Anemia Treatment
- Iron Metabolism and Disorders
- Multiple Myeloma Research and Treatments
Genetics top 2%
- Hemoglobinopathies and Related Disorders
- Chronic Lymphocytic Leukemia Research

Papers in ⓘ

Hematology 35
- Erythropoietin and Anemia Treatment 27
- Iron Metabolism and Disorders 16
- Acute Myeloid Leukemia Research 5
Genetics 17
- Hemoglobinopathies and Related Disorders 14

Co-authors: Anders Österborg (8 shared papers)Yvonne Brandberg (2 shared papers)Steven Fishbane (2 shared papers)S Patni (2 shared papers)Stefanie Howaldt (2 shared papers)Francesco Locatelli (2 shared papers)János Szebeni (2 shared papers)David S. Rampton (2 shared papers)
Journals: Blood (7 papers)British Journal of Haematology (5 papers)Journal of Clinical Oncology (5 papers)Medical Oncology (4 papers)European Journal Of Haematology (3 papers)
Partner nations: Sweden United States Austria

In The Last Decade

Michael Hedenus

41 papers receiving 1.6k citations

Peers

Countries citing papers authored by Michael Hedenus

Since Specialization

Citations

This map shows the geographic impact of Michael Hedenus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Hedenus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Hedenus more than expected).

Fields of papers citing papers by Michael Hedenus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Hedenus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Hedenus. The network helps show where Michael Hedenus may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael Hedenus, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Hedenus Line = papers co-authored together Michael Hedenus links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 42 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double‐blind, placebo‐controlled study British Journal of Haematology ·Michael Hedenus, Magnus Adriansson, Jesús F. San Miguel, Mark H.H. Kramer, Martin R. Schipperus, Eeva Juvonen, Kerry Taylor, Andrew Belch, Albert Altés, Giovanni Martinelli, David I. Watson, James Matcham, Gregory Rossi, Timothy J. Littlewood	2003	267
2	Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Erythropoietin, Epoetin Beta, in Hematologic Malignancies Journal of Clinical Oncology ·Anders Österborg, Yvonne Brandberg, В. З. Молостова, Genadi Iosava, Abdulkadyrov Km, Michael Hedenus, Diethelm Messinger	2002	236
3	Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management Haematologica ·David S. Rampton, J. Folkersen, Steven Fishbane, Michael Hedenus, Stefanie Howaldt, Francesco Locatelli, S Patni, János Szebeni, (unknown)	2014	220
4	Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management British Journal of Pharmacology ·János Szebeni, Steven Fishbane, Michael Hedenus, Stefanie Howaldt, Francesco Locatelli, S Patni, David S. Rampton, (unknown), J. Folkersen	2015	110
5	Evaluation of a Single Dose of Ferric Carboxymaltose in Fatigued, Iron-Deficient Women – PREFER a Randomized, Placebo-Controlled Study PLoS ONE ·Bernard Favrat, Katharina Balck, Christian Breymann, Michael Hedenus, Thomas Keller, Anna Mezzacasa, Christoph Gasché	2014	99
6	Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double‐blind placebo‐controlled trial British Journal of Haematology ·H Brincker, (unknown), Niels Abildgaard, Peter Gimsing, Ingemar Turesson, Michael Hedenus, J. Ford, Albert Kandra	1998	83
7	Randomized, dose‐finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies British Journal of Haematology ·Michael Hedenus, Søren B. Hansen, Kerry Taylor, Chris Arthur, Bertold Emmerich, Claire Dewey, David I. Watson, Gregory Rossi, Anders Österborg, (unknown)	2002	75
8	Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. Journal of Clinical Oncology ·Gunnar Juliusson, Dag Heldal, Erik Hippe, Michael Hedenus, Christer Malm, Karen Wallman, C M Stolt, S A Evensen, Freidoun Albertioni, Geir E. Tjønnfjord	1995	67
9	Impact of epoetin‐β on survival of patients with lymphoproliferative malignancies: long‐term follow up of a large randomized study* British Journal of Haematology ·Anders Österborg, Yvonne Brandberg, Michael Hedenus	2005	46
10	Darbepoetin Alfa for the Treatment of Chemotherapy-Induced Anemia: Disease Progression and Survival Analysis From Four Randomized, Double-Blind, Placebo-Controlled Trials Journal of Clinical Oncology ·Michael Hedenus, Johan Vansteenkiste, Dusan Kotasek, Matthew Austin, Rafael G. Amado	2005	45
11	Results of risk‐adapted therapy in acute myeloid leukaemia. A long‐term population‐based follow‐up study European Journal Of Haematology ·Anders Wåhlin, Rolf Billström, Ove Björ, Tomas Ahlgren, Michael Hedenus, Martin Höglund, Anders Lindmark, Berit Markevärn, Bo Nilsson, Bengt Sallerfors, Mats Brune	2009	34
12	Efficacy of Darbepoetin Alfa in Alleviating Fatigue and the Effect of Fatigue on Quality of Life in Anemic Patients with Lymphoproliferative Malignancies Journal of Pain and Symptom Management ·Timothy J. Littlewood, Joel Kallich, Jesús F. San Miguel, Lisa Hendricks, Michael Hedenus	2006	33
13	Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy Medical Oncology ·Michael Hedenus, Torbjörn Karlsson, Heinz Ludwig, B. Rzychon, Marcel Felder, Bernard Roubert, Gunnar Birgegård	2014	31
14	A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia Supportive Care in Cancer ·H Ludwig, Matti Aapro, C. Bokemeyer, John A. Glaspy, Michael Hedenus, Timothy J. Littlewood, Anders Österborg, B. Rzychon, Daniell Mitchell, Yves Béguin	2014	31
15	A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia Leukemia Research ·Astrid Gruber, Magnus Björkholm, L Brinch, Stein A. Evensen, Bengt Gustavsson, Michael Hedenus, Gunnar Juliusson, Eva Löfvenberg, Ingerid Nesthus, Bengt Simonsson, Malvin Sjo, Leif Stenke, Jon Magnus Tangen, Ulf Tidefelt, Ann‐Mari Udén, Christer Paul, Jan Liliemark	2003	26
16	Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia Cancer Chemotherapy and Pharmacology ·Anders Wåhlin, P. H�rnsten, Michael Hedenus, Claes Malm	1991	19
17	Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus ≥10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial BMC Cancer ·Johan Vansteenkiste, Michael Hedenus, Pere Gascón, Carsten Bokemeyer, Heinz Ludwig, Jan B. Vermorken, Lisa Hamilton, Ken Bridges, B. Pujol	2009	18
18	The role of iron supplementation during epoietin treatment for cancer-related anemia Medical Oncology ·Michael Hedenus, Gunnar Birgegård	2008	18
19	Effects of erythropoiesis-stimulating agents on survival and other outcomes in patients with lymphoproliferative malignancies: a study-level meta-analysis Leukemia & lymphoma ·Michael Hedenus, Anders Österborg, Dianne Tomita, Chet Bohac, Bertrand Coiffier	2012	14
20	Correction/Maintenance Dosing (Front Loading) of Darbepoetin alfa: Final Results from a Randomized Phase 3 Active Controlled Trial. Blood ·Dusan Kotasek, J.-L. Canon, Jesús F. San Miguel, Michael Hedenus, Lisa Hendricks, Giuseppe Rossi, Kerry Taylor	2004	14

About Michael Hedenus

Michael Hedenus is a scholar working on Hematology, Genetics, Oncology, Pediatrics, Perinatology and Child Health and Public Health, Environmental and Occupational Health, having authored 42 papers that have together received 1.6k indexed citations. Recurring topics across this work include Erythropoietin and Anemia Treatment (27 papers), Iron Metabolism and Disorders (16 papers), Hemoglobinopathies and Related Disorders (14 papers), Pharmacological Effects and Toxicity Studies (5 papers), Acute Myeloid Leukemia Research (5 papers), Blood transfusion and management (4 papers), Acute Lymphoblastic Leukemia research (4 papers) and Cancer Treatment and Pharmacology (3 papers). The work is most often cited by research in Hematology (1.3k citations), Genetics (532 citations), Biochemistry (273 citations), Oncology (359 citations) and Nephrology (86 citations). Michael Hedenus has collaborated with scholars based in Sweden, United States and Austria. Frequent co-authors include Anders Österborg, Yvonne Brandberg, Steven Fishbane, S Patni, Stefanie Howaldt, Francesco Locatelli, János Szebeni, David S. Rampton, Diethelm Messinger and Abdulkadyrov Km. Their work appears in journals such as Blood, British Journal of Haematology, Journal of Clinical Oncology, Medical Oncology and European Journal Of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact